Order Tests Now

EPISEEK® Multi-Cancer Early Detection

Invest in your patients’ health.

The Precision Epigenomics liquid biopsy test, EPISEEK, is a groundbreaking multi-cancer early detection (MCED) test that uses a simple blood draw to identify DNA changes associated with over 60 types of cancer. By detecting hypermethylated DNA loci—areas commonly hypermethylated across various cancers—EPISEEK enables early, accurate detection, even in individuals without prior signs of cancer.

Using advanced technology software, epigenomic modifications are analyzed. This technology is cost-effective, precise, and minimally invasive, and it may detect cancer earlier than imaging. It is also more accessible than a tissue biopsy.

Order Tests Now

The EPISEEK Test Detects Cancers Missed by Standard Screening

Brain

Lung & Bronchus

Breast

Colon & Rectum

Prostate

Bladder

Kidney

Pancreas

Uterine and Cervical

Lymphoma

Myeloma & Leukemia

Thyroid

Oral

Liver

Esophagus

Ovarian

Skin

Feel in Control of Your Health

Talk to your healthcare professional about scheduling your EPISEEK multi-cancer early detection test.

%

5-Year Survival Rate

when cancer is detected early*

*The American Cancer Society

The Right Provider Is Committed to Keeping You Healthy

“I use EPISEEK alongside standard guideline-based cancer screenings for my patients. It offers exceptional specificity and is an excellent tool for early detection. EPISEEK screens for the top 10 leading causes of cancer-related deaths, including brain cancer, and is available at a more accessible price point than alternatives. It’s a great choice for my patients to help with early detection of cancer.”

– CARL SEGER, MD

More Than Just an Earlier Cancer Detection Test

It’s peace of mind.

Order Tests Now

Using a specificity of 99.5%, EPISEEK is predicted to have a positive predictive value (PPV) of 64.9% and a negative predictive value (NPV) of 99.5% in patients 50 years and older.

For aggressive stages I and II cancers that do not have widely adopted screening—such as bladder, esophagus, head and neck SCC, lung, pancreas, and uterine—EPISEEK has a sensitivity of 62%. At stage III, which is still operable in many cases, the sensitivity for aggressive cancers is 80%.